Objective： To study the role of nuclear factor-kappa B（NF- κB） in cholesterol efflux from THP-1 derived-foam cells treated with Angiotensin Ⅱ（Ang Ⅱ ）. Methods：Cultured THP-1 derived-foam cells were treated wi...Objective： To study the role of nuclear factor-kappa B（NF- κB） in cholesterol efflux from THP-1 derived-foam cells treated with Angiotensin Ⅱ（Ang Ⅱ ）. Methods：Cultured THP-1 derived-foam cells were treated with Ang Ⅱ or preincubated with tosyl-phenylalanine chloromethyl-ketone（TPCK） NF- κB inhibitor. The levels of activated NF- κB in the cells were examined by sandwich ELISA, Cellular cholesterol content was studied by electron microscopy scanning and zymochemistry via fluorospectrophotometer and cholesterol effiux was detected by scintillation counting technique. ABCA1 mRNA and protein were quantified by RT-PCR and Western blotting. Results：Addition of TPCK to the cells before Ang Ⅱ stimulation attenuated the response of NF- κB p65 nuclear translocation induced by Ang Ⅱ and showed no peak in foam cells group and caused a reduction in cholesterol content and an increase in cholesterol efflux by 24.1%（P〈 0.05） and 41.1%（P〈 0.05） respectively, when compared with Ang Ⅱ group. In accordance, the ABCA1 mRNA and protein were increased by 30% and 19%（P 〈 0.05） respectively, when compared with Ang Ⅱ group. Conclusion：Ang Ⅱ can downregulate ABCA1 in THP-1 derived-foam cells via NF- K B, which leads to less cholesterol effiux and the increase of cholesterol content with the consequence of the promotion of atherosclerosis.展开更多
Introduction:ATP-binding cassette subfamily B member 1(ABCB1) and subfamily C member 10(ABCCIO) proteins are efflux transporters that couple the energy derived from ATP hydrolysis to the translocation of toxic substan...Introduction:ATP-binding cassette subfamily B member 1(ABCB1) and subfamily C member 10(ABCCIO) proteins are efflux transporters that couple the energy derived from ATP hydrolysis to the translocation of toxic substances and chemotherapeutic drugs out of cells.Cabazitaxel is a novel taxane that differs from paclitaxel by its lower affinity for ATP-binding cassette(ABC) transporters.Methods:We determined the effects of cabazitaxel,a novel tubulin-binding taxane,and paclitaxel on paclitaxelresistant,ABCB1-overexpressing KB-C2 and LLC-MDR1-WT cells and paclitaxel-resistant,ABCC10-overexpressing HEK293/ABCC10 cells by calculating the degree of drug resistance and measuring ATPase activity of the ABCB1 transporter.Results:Decreased resistance to cabazitaxel compared with paclitaxel was observed in KB-C2,LLC-MDR1-WT,and HEK293/ABCC10 cells.Moreover,cabazitaxel had low efficacy,whereas paclitaxel had high efficacy in stimulating the ATPase activity of ABCB1,indicating a direct interaction of both drugs with the transporter.Conclusion:ABCB1 and ABCC10 are not primary resistance factors for cabazitaxel compared with paclitaxel,suggesting that cabazitaxel may have a low affinity for these efflux transporters.展开更多
Various previous studies have found a negative cor-relation between the risk of cardiovascular events and serum high-density lipoprotein(HDL) cholesterol levels. The reverse cholesterol transport, a pathway of choles-...Various previous studies have found a negative cor-relation between the risk of cardiovascular events and serum high-density lipoprotein(HDL) cholesterol levels. The reverse cholesterol transport, a pathway of choles-terol from peripheral tissue to liver which has several potent antiatherogenic properties. For instance, the particles of HDL mediate to transport cholesterol from cells in arterial tissues, particularly from atherosclerotic plaques, to the liver. Both ATP-binding cassette trans-porters(ABC) A1 and ABCG1 are membrane cholesterol transporters and have been implicated in mediating cholesterol effluxes from cells in the presence of HDL and apolipoprotein A-I, a major protein constituent of HDL. Previous studies demonstrated that ABCA1 and ABCG1 or the interaction between ABCA1 and ABCG1 exerted antiatherosclerotic effects. As a therapeutic approach for increasing HDL cholesterol levels, much focus has been placed on increasing HDL cholesterol levels as well as enhancing HDL biochemical functions. HDL therapies that use injections of reconstituted HDL, apoA-I mimetics, or full-length apoA-I have shown dramatic effectiveness. In particular, a novel apoA-I mi-metic peptide, Fukuoka University ApoA-I Mimetic Pep-tide, effectively removes cholesterol via specific ABCA1 and other transporters, such as ABCG1, and has an an-tiatherosclerotic effect by enhancing the biological func-tions of HDL without changing circulating HDL choles-terol levels. Thus, HDL-targeting therapy has significant atheroprotective potential, as it uses lipid transporter-targeting agents, and may prove to be a therapeutic tool for atherosclerotic cardiovascular diseases.展开更多
目的探讨ATP结合盒转运蛋白B1(ABCB1)及羧酸酯酶1(CES1)基因多态性与服用达比加群酯的患者药物谷浓度的相关性。方法选取2018年3月-2021年11月在福州某医院诊断为非瓣膜性房颤的69例患者作为研究对象。检测患者ABCB1及CES1的单核苷酸多...目的探讨ATP结合盒转运蛋白B1(ABCB1)及羧酸酯酶1(CES1)基因多态性与服用达比加群酯的患者药物谷浓度的相关性。方法选取2018年3月-2021年11月在福州某医院诊断为非瓣膜性房颤的69例患者作为研究对象。检测患者ABCB1及CES1的单核苷酸多态性位点以及基因型,采用抗Ⅱa因子显色法测定患者服用达比加群酯后药物的谷浓度,分析ABCB1及CES1基因多态性与谷浓度的相关性,进一步研究相关位点对谷浓度达标的影响。结果本研究共发现11个单核苷酸多态性位点,且ABCB1 rs2235013与ABCB1 rs2235033处于连锁不平衡状态(D’=0.96,r2=0.82)。但ABCB1基因多态性对达比加群谷浓度无显著影响(P>0.05)。CES1 rs2302719突变型(TG,GG)患者的达比加群谷浓度高于野生型(TT)(51.98±8.06 vs 42.44±3.88,57.71±9.06 vs 42.44±3.88),并且CES1 rs2302719突变型(TG,GG)是患者谷浓度达标的保护因素,结果具有统计学意义(P<0.05)。结论ABCB1基因多态性对达比加群谷浓度的影响还需进一步探索。CES1 rs2302719次要等位基因(G)可增加达比加群谷浓度,并且不良反应的发生率可能更低。展开更多
目的:探讨姜黄素对APP/PS1双转基因鼠海马组织中三磷酸腺苷结合盒转运子A1(ATP binding cassette transport protein A1,ABCA1)和载脂蛋白A1(apolipoprotein A1,apoA1)的表达及血清中总胆固醇(total cholesterol,TC)和高密度脂蛋白(high...目的:探讨姜黄素对APP/PS1双转基因鼠海马组织中三磷酸腺苷结合盒转运子A1(ATP binding cassette transport protein A1,ABCA1)和载脂蛋白A1(apolipoprotein A1,apoA1)的表达及血清中总胆固醇(total cholesterol,TC)和高密度脂蛋白(high-density lipoprotein,HDL)含量的影响。方法:用APP/PS1双转基因鼠建立阿尔茨海默病(Alzheimer’s disease,AD)模型,不同浓度姜黄素饲料喂养6个月。免疫组化SP法检测转基因鼠的海马组织CA1区ABCA1和apoA1的表达变化。胆固醇酶法比色法检测血清中TC和HDL的含量。结果:经过不同浓度姜黄素饲喂转基因鼠后,其海马组织CA1区ABCA1和apoA1的表达增加(P=0.005和0.003;P=0.025和0.001),且血清中HDL的含量也随之增加,TC的含量逐渐减少,其差异均有统计学意义(P=0.041和0.010;P=0.046和0.002)。结论:ABCA1在AD的发生发展中起着重要的作用,姜黄素可能是通过增加ABCA1表达和升高apoA1和HDL含量降低胆固醇水平。展开更多
基金the National Basic Research and Development Program of China(973 Program, No.2007CB512000) (Sub-Project,No.2007CB512005)
文摘Objective： To study the role of nuclear factor-kappa B（NF- κB） in cholesterol efflux from THP-1 derived-foam cells treated with Angiotensin Ⅱ（Ang Ⅱ ）. Methods：Cultured THP-1 derived-foam cells were treated with Ang Ⅱ or preincubated with tosyl-phenylalanine chloromethyl-ketone（TPCK） NF- κB inhibitor. The levels of activated NF- κB in the cells were examined by sandwich ELISA, Cellular cholesterol content was studied by electron microscopy scanning and zymochemistry via fluorospectrophotometer and cholesterol effiux was detected by scintillation counting technique. ABCA1 mRNA and protein were quantified by RT-PCR and Western blotting. Results：Addition of TPCK to the cells before Ang Ⅱ stimulation attenuated the response of NF- κB p65 nuclear translocation induced by Ang Ⅱ and showed no peak in foam cells group and caused a reduction in cholesterol content and an increase in cholesterol efflux by 24.1%（P〈 0.05） and 41.1%（P〈 0.05） respectively, when compared with Ang Ⅱ group. In accordance, the ABCA1 mRNA and protein were increased by 30% and 19%（P 〈 0.05） respectively, when compared with Ang Ⅱ group. Conclusion：Ang Ⅱ can downregulate ABCA1 in THP-1 derived-foam cells via NF- K B, which leads to less cholesterol effiux and the increase of cholesterol content with the consequence of the promotion of atherosclerosis.
基金supported by funds from the National Institutes of Health (1R15CA143701)St.John's University Research Seed Grant(579-1110-7002) to Dr.Zhe-Sheng Chen.Drs.Suneet ShuklaSuresh V.Ambudkar were supported by the Intramural Research Program,Center for Cancer Research, National Cancer Institute,National Institutes of Health
文摘Introduction:ATP-binding cassette subfamily B member 1(ABCB1) and subfamily C member 10(ABCCIO) proteins are efflux transporters that couple the energy derived from ATP hydrolysis to the translocation of toxic substances and chemotherapeutic drugs out of cells.Cabazitaxel is a novel taxane that differs from paclitaxel by its lower affinity for ATP-binding cassette(ABC) transporters.Methods:We determined the effects of cabazitaxel,a novel tubulin-binding taxane,and paclitaxel on paclitaxelresistant,ABCB1-overexpressing KB-C2 and LLC-MDR1-WT cells and paclitaxel-resistant,ABCC10-overexpressing HEK293/ABCC10 cells by calculating the degree of drug resistance and measuring ATPase activity of the ABCB1 transporter.Results:Decreased resistance to cabazitaxel compared with paclitaxel was observed in KB-C2,LLC-MDR1-WT,and HEK293/ABCC10 cells.Moreover,cabazitaxel had low efficacy,whereas paclitaxel had high efficacy in stimulating the ATPase activity of ABCB1,indicating a direct interaction of both drugs with the transporter.Conclusion:ABCB1 and ABCC10 are not primary resistance factors for cabazitaxel compared with paclitaxel,suggesting that cabazitaxel may have a low affinity for these efflux transporters.
文摘Various previous studies have found a negative cor-relation between the risk of cardiovascular events and serum high-density lipoprotein(HDL) cholesterol levels. The reverse cholesterol transport, a pathway of choles-terol from peripheral tissue to liver which has several potent antiatherogenic properties. For instance, the particles of HDL mediate to transport cholesterol from cells in arterial tissues, particularly from atherosclerotic plaques, to the liver. Both ATP-binding cassette trans-porters(ABC) A1 and ABCG1 are membrane cholesterol transporters and have been implicated in mediating cholesterol effluxes from cells in the presence of HDL and apolipoprotein A-I, a major protein constituent of HDL. Previous studies demonstrated that ABCA1 and ABCG1 or the interaction between ABCA1 and ABCG1 exerted antiatherosclerotic effects. As a therapeutic approach for increasing HDL cholesterol levels, much focus has been placed on increasing HDL cholesterol levels as well as enhancing HDL biochemical functions. HDL therapies that use injections of reconstituted HDL, apoA-I mimetics, or full-length apoA-I have shown dramatic effectiveness. In particular, a novel apoA-I mi-metic peptide, Fukuoka University ApoA-I Mimetic Pep-tide, effectively removes cholesterol via specific ABCA1 and other transporters, such as ABCG1, and has an an-tiatherosclerotic effect by enhancing the biological func-tions of HDL without changing circulating HDL choles-terol levels. Thus, HDL-targeting therapy has significant atheroprotective potential, as it uses lipid transporter-targeting agents, and may prove to be a therapeutic tool for atherosclerotic cardiovascular diseases.
文摘目的探讨ATP结合盒转运蛋白B1(ABCB1)及羧酸酯酶1(CES1)基因多态性与服用达比加群酯的患者药物谷浓度的相关性。方法选取2018年3月-2021年11月在福州某医院诊断为非瓣膜性房颤的69例患者作为研究对象。检测患者ABCB1及CES1的单核苷酸多态性位点以及基因型,采用抗Ⅱa因子显色法测定患者服用达比加群酯后药物的谷浓度,分析ABCB1及CES1基因多态性与谷浓度的相关性,进一步研究相关位点对谷浓度达标的影响。结果本研究共发现11个单核苷酸多态性位点,且ABCB1 rs2235013与ABCB1 rs2235033处于连锁不平衡状态(D’=0.96,r2=0.82)。但ABCB1基因多态性对达比加群谷浓度无显著影响(P>0.05)。CES1 rs2302719突变型(TG,GG)患者的达比加群谷浓度高于野生型(TT)(51.98±8.06 vs 42.44±3.88,57.71±9.06 vs 42.44±3.88),并且CES1 rs2302719突变型(TG,GG)是患者谷浓度达标的保护因素,结果具有统计学意义(P<0.05)。结论ABCB1基因多态性对达比加群谷浓度的影响还需进一步探索。CES1 rs2302719次要等位基因(G)可增加达比加群谷浓度,并且不良反应的发生率可能更低。
文摘目的:探讨姜黄素对APP/PS1双转基因鼠海马组织中三磷酸腺苷结合盒转运子A1(ATP binding cassette transport protein A1,ABCA1)和载脂蛋白A1(apolipoprotein A1,apoA1)的表达及血清中总胆固醇(total cholesterol,TC)和高密度脂蛋白(high-density lipoprotein,HDL)含量的影响。方法:用APP/PS1双转基因鼠建立阿尔茨海默病(Alzheimer’s disease,AD)模型,不同浓度姜黄素饲料喂养6个月。免疫组化SP法检测转基因鼠的海马组织CA1区ABCA1和apoA1的表达变化。胆固醇酶法比色法检测血清中TC和HDL的含量。结果:经过不同浓度姜黄素饲喂转基因鼠后,其海马组织CA1区ABCA1和apoA1的表达增加(P=0.005和0.003;P=0.025和0.001),且血清中HDL的含量也随之增加,TC的含量逐渐减少,其差异均有统计学意义(P=0.041和0.010;P=0.046和0.002)。结论:ABCA1在AD的发生发展中起着重要的作用,姜黄素可能是通过增加ABCA1表达和升高apoA1和HDL含量降低胆固醇水平。
